Tempus AI

Tempus AI (NASDAQ: TEM) is a clinical AI and precision medicine company that uses the largest multimodal clinical dataset in the industry — 40+ million records and 1.1 billion healthcare records — to help oncologists select the most effective targeted therapies. Founded by Eric Lefkofsky, Tempus combines genomic testing, AI software, and data licensing with $1.27 billion in 2025 revenue. In April 2026 its collaboration with Gilead Sciences was expanded into a multi-year agreement giving Gilead enterprise-wide access to the Lens platform plus dedicated analytical services across its oncology pipeline, a sign of Tempus moving from project-specific data licensing toward embedded, enterprise-scale deals with pharma.